LAVA 1207
Alternative Names: LAVA-1207Latest Information Update: 27 Mar 2024
At a glance
- Originator VU University Medical Center
- Developer Lava Therapeutics; Merck & Co
- Class Antineoplastics; Bispecific antibodies; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Prostate cancer
Most Recent Events
- 20 Mar 2024 Adverse events data from a phase I/IIa trial in Prostate cancer released by LAVA Therapeutics
- 25 Jan 2024 LAVA Therapeutics and Merck & Co., Inc., Rahway, NJ, USA enters into a clinical trial collaboration and supply agreement for Phase-I/II clinical trial in Prostate cancer (Hormone refractory, Metastatic disease, Second-line therapy or greater)
- 22 Aug 2023 Lava Therapeutics plans a pivotal trial for Prostate cancer